Pharma Focus Asia

Fusion Pharmaceuticals to Open Radiopharmaceutical Manufacturing Facility in Canada

Introduction:

Fusion Pharmaceuticals plans to open state-of-the-art radiopharmaceutical manufacturing facility. 

Features:

This facility covers an area of 27,000 square feet and is designed to follow strict quality standards.

The new facility will create more than 100,000 doses of these targeted alpha therapies every year. This state-of-the-art facility is designed with the capacity to engage in both clinical and commercial scale manufacturing.

Its primary objective is to cater to the production needs of targeted alpha therapies (TATs) in response to the growing demand within the pipeline.

This facility is strategically situated alongside the research and development labs and McMaster University and enables to easily hire experienced talent to execute on clinical and future commercial plans.

The facility' is expected to launch in 2024.

Specifications:

Name   Fusion Pharmaceuticals
Type   New Construction
Year   2024
 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024